Novel Biomarkers for Thrombosis Risk Prediction in Non–Small-Cell Lung Cancer: Insights from Recent Evidence
Venous thromboembolism (VTE) represents a significant cause of morbidity and mortality in patients with cancer,...
Most Read
Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer
The authors of a recent study1 have taken a novel look at the impact of venous thromboembolism (VTE) among...
Evolving data on cardiovascular complications in cancer
During the 11th ICTHIC, Hugo Ten Cate talked about the evolving data on cardiovascular complications in cancer. Here,...
Risk assessment of thromboembolic events in hospitalized cancer patients: the INDICATE study
Background Thromboprophylaxis (TP) with low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs)...
ARTET FOUNDATION PARTNERSHIP
ICTHIC Magazine is glad to announce the new partnership with ARTET foundation. ARTET (Association for the Research in...
Treatment of VTE in the colorectal cancer patient
In clinical practice, cancer-associated thrombosis (CAT) is a frequent phenomenon among colorectal cancer (CRC)...
Risk of thromboembolism in cancer patients with Port-a-Cath. Results and implications of the ONCOCIP study
The normal experience of cancer patients who receive an implantable venous access device (Port-a-Cath) for chemotherapy...
Benjamin Brenner
Benjamin Brenner Director, Hematology and Bone Marrow Transplantation Institute – Director, Division of Internal...
Does the use of direct oral anticoagulants improve adherence compared to low-molecular-weight heparin (LMWH) in patients with cancer?
Patients with cancer represent a major challenge for venous thromboembolism (VTE) treatment because of their higher...
How to improve patient’s awareness about the risk of cancer-associated thrombosis
Although patients with cancer have a four-to-five-fold increased risk of venous thromboembolism (VTE) compared with the...